You are here
Novartis puts pressure on Roche with cheap copy of Rituxan
SWITZERLAND'S Novartis increased pressure on Roche's ageing stable of big-selling drugs on Monday by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases.
Rixathon, from Novartis's Sandoz generics
- CALL +65 6388 3838
- EMAIL firstname.lastname@example.org